Indeed, activators of Nrf2 (nuclear factor erythroid 2-related factor 2; a member of the Cap ‘n’ Collar [CNC] transcription factor family), which is the master regulator of antioxidant genes [13,14], are investigated in ongoing clinical trials as medicines for treating kidney disease [15,16,17]. This evidence concerns the gene NFE2L2 and kidney disorder.